福元医药(601089) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥802,722,388.57, representing a decrease of 2.01% compared to the same period last year[4]. - Net profit attributable to shareholders was ¥132,577,291.60, an increase of 16.60% year-on-year[4]. - Basic and diluted earnings per share were both ¥0.28, reflecting a growth of 16.67% compared to the previous year[4]. - Total operating revenue for Q1 2024 was ¥802,722,388.57, a decrease of 2.8% from ¥819,176,868.99 in Q1 2023[20]. - Net profit for Q1 2024 reached ¥133,524,586.60, representing an increase of 15.9% compared to ¥115,180,784.67 in Q1 2023[22]. - Earnings per share for Q1 2024 were ¥0.28, up from ¥0.24 in Q1 2023[22]. Cash Flow - The net cash flow from operating activities increased significantly by 73.41%, amounting to ¥143,883,044.52, due to increased sales collections and tax deductions[7]. - In Q1 2024, the cash inflow from operating activities totaled $863,597,324.97, an increase of 6.7% compared to $809,366,657.48 in Q1 2023[25]. - The net cash flow from operating activities was $143,883,044.52, significantly up from $82,973,037.29 in the same quarter last year, representing a growth of 73%[25]. - Cash outflow for investing activities was $99,900,685.86, down from $418,604,806.32 in Q1 2023, indicating a reduction of 76.1%[26]. - The net cash flow from investing activities was -$91,329,568.36, an improvement from -$418,423,521.32 year-over-year[26]. - Cash inflow from financing activities was $39,900,000.00, slightly down from $45,000,000.00 in Q1 2023[26]. - The net cash flow from financing activities was -$161,398,217.07, compared to a positive $28,207,293.88 in the previous year[26]. - The ending cash and cash equivalents balance was $2,395,655,623.17, a decrease from $2,540,939,325.65 at the beginning of the quarter[26]. - Cash received from tax refunds was $833,878.94, up from $683,300.00 in the same quarter last year[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,493,909,207.77, a decrease of 1.18% from the end of the previous year[5]. - The company's total assets amounted to ¥4,493,909,207.77, down from ¥4,547,790,301.79 in Q1 2023[21]. - The total liabilities decreased to RMB 963,856,813.12 from RMB 998,375,562.87, a decline of about 3.5%[17]. - The total liabilities as of Q1 2024 were ¥1,032,653,382.94, a decrease from ¥1,071,251,195.74 in the previous year[21]. - The company's cash and cash equivalents decreased to RMB 2,421,964,605.09 from RMB 2,530,809,346.00, reflecting a decline of approximately 4.3%[16]. - Accounts receivable decreased to RMB 334,080,231.03 from RMB 346,134,907.22, a reduction of about 3.5%[16]. - The company's inventory increased to RMB 329,509,170.73 from RMB 307,419,355.37, representing an increase of approximately 7.2%[16]. - The company’s short-term borrowings decreased to RMB 49,940,070.00 from RMB 55,050,513.92, a reduction of approximately 9.1%[17]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 25,530[9]. - The top ten shareholders held a total of 36.7% of the shares, with the largest shareholder holding 176,316,354 shares[10]. - The company reported a decrease in total equity attributable to shareholders by 0.47% to ¥3,452,185,860.68[5]. - The total equity attributable to shareholders was ¥3,452,185,860.68, slightly down from ¥3,468,416,436.90 in Q1 2023[21]. Non-Recurring Items - Non-recurring gains and losses amounted to ¥9,019,229.97, primarily from the disposal of non-current assets and government subsidies[7]. Share Repurchase - The company repurchased a total of 10,018,000 shares, accounting for 2.09% of the total share capital, with a total transaction amount of RMB 148,612,482.92[13]. - The company plans to repurchase shares worth between RMB 100 million and RMB 200 million, with a maximum repurchase price of RMB 24.10 per share[12].